Pharvaris Oral HAE Candidate Heading Into Phase II In 2021
$80m Series C Completed
European biotech Pharvaris has received series C funding to support its novel potential therapy for hereditary angioedema, in a competitive sector of drug development.
You may also be interested in...
The company sees KVD900 as potentially “ideal” for patients using on-demand and prophylactic therapy, given the existing need to carry backup on-demand medications.
IPO Edition: Sana leads the group with a $587.5m initial public offering, while Immunocore and Bolt follow with $200m-plus IPOs. The 10 newly public companies generated a 43.3% average return on 8 Feb.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.